Clinical Trial Update: Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab plus capecitabine as adjuvant therapy for triple-negative breast cancer, reporting on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tecentriq (atezolizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING